Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 7/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 7/20 | 0.35 |
| ▸ | PPARA | Q07869 | 7/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | PPARD | Q03181 | 2/20 | 0.33 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.33 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.33 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10107038 | 0.88 | NR1H4 (0.40) | NR1H4LMNAPTBP1SMN1; SMN2PPARG | |
| SCHEMBL10101749 | 0.79 | MAOB (0.42) | LMNAPTBP1SMN1; SMN2PPARGPPARA | |
| SCHEMBL15255331 | 0.78 | NPC1 (0.42) | SMN1; SMN2PPARGPPARAGRIN2BMRGPRX4 | |
| SCHEMBL10102074 | 0.76 | MAOB (0.45) | LMNAPTBP1SMN1; SMN2PPARGPPARA | |
| SCHEMBL10102038 | 0.74 | SMN1; SMN2 (0.51) | LMNAPTBP1SMN1; SMN2PPARGPPARA | |
| SCHEMBL10101744 | 0.74 | S1PR1 (0.41) | LMNAPTBP1SMN1; SMN2PPARGPPARA | |
| SCHEMBL10102011 | 0.74 | NPC1 (0.46) | LMNAPTBP1SMN1; SMN2PPARGPPARA | |
| SCHEMBL12557400 | 0.72 | PPARG (0.41) | NR1H4SMN1; SMN2PPARGPPARAS1PR1 | |
| SCHEMBL10102056 | 0.72 | SMN1; SMN2 (0.44) | LMNAPTBP1SMN1; SMN2PPARGPPARA | |
| SCHEMBL10102036 | 0.71 | NPC1 (0.50) | LMNASMN1; SMN2PPARGPPARAS1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046255-A1 | NON-STEROIDAL COMPOUNDS | THE UNIVERSITY OF MELBOURNE of ROYAL PARADE PARKVILLE (AU) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046255-A1 | NON-STEROIDAL COMPOUNDS | PTGES2, PTGES, PTGES3 | NR1H4 27/4885LMNA 2636/4885PTBP1 2831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.